Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Bojanini, Leyla [1 ]
Gupta, Neel [1 ]
Khaki, Ali Raza [1 ,2 ]
机构：
[1] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA
[2] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
来源：
ONCOLOGIST | 2023年 / 28卷 / 09期
关键词：
D O I：
10.1093/oncolo/oyad204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：750 / 751
页数：2
相关论文
共 50 条
  • [31] Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma
    Ahmed, Gulrayz
    Furqan, Fateeha
    Nasrollahi, Elham
    Hamadani, Mehdi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 705 - 715
  • [32] Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
    Abdulhaq, Haifaa
    Hwang, Andrew
    Mahmood, Omar
    ONCOTARGETS AND THERAPY, 2023, 16 : 617 - 629
  • [33] TREATMENT PREFERENCES AMONG PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES
    Liu, F. F.
    Collacott, H.
    Clarke, H.
    Michaels-Igbokwe, C.
    VALUE IN HEALTH, 2023, 26 (06) : S316 - S316
  • [34] Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: a discrete choice experiment
    Birch, Kelly
    Snider, Julia T.
    Chiu, Kevin
    Baumgardner, Jim
    Wade, Sally W.
    Shah, Gunjan
    FUTURE ONCOLOGY, 2022, 18 (25) : 2791 - 2804
  • [35] TREATMENT PATTERNS AND COST ANALYSIS AMONG PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Nabhan, C.
    Myerscough, C.
    Kish, J.
    Chung, J.
    Chopra, D.
    VALUE IN HEALTH, 2019, 22 : S82 - S82
  • [36] Glofit-GemOx: a new treatment paradigm in relapsed or refractory diffuse large B-cell lymphoma?
    Sureda, Anna
    Pavlosky, Astrid
    LANCET, 2024, 404 (10466): : 1899 - 1901
  • [37] Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma
    Meyer, Kellie
    Huang, Danmeng
    O'Day, Ken
    Lahue, Betsy J.
    Wang, Anthony
    Mutebi, Alex
    Brodkin, Samantha
    Jun, Monika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
    Frontzek, Fabian
    Karsten, Imke
    Schmitz, Norbert
    Lenz, Georg
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [39] Bendamustine plus Rituximab as Treatment for Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Vacirca, Jeffrey
    Tabbara, Imad
    Acs, Peter
    Shumaker, Grace
    BLOOD, 2010, 116 (21) : 1157 - 1157
  • [40] Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma
    Skrabek, R.
    Assouline, S.
    Christofides, A.
    MacDonald, D.
    Prica, A.
    Sangha, R.
    Matthews, B. A.
    Sehn, L. H.
    CURRENT ONCOLOGY, 2019, 26 (04) : 253 - 265
12345